Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Venetoclax-based therapies in patients with Relapsed/Refractory T-cell prolymphocytic leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

FVFrancisco VegaDSDeepa SampathAFAlessandra Ferrajoli

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows venetoclax-based therapies yield 46% response rate in relapsed/refractory T-PLL, suggesting improved survival outcomes in selective patients.

Key Points

  • The study evaluates the efficacy of venetoclax-based regimens in patients with relapsed/refractory T-cell prolymphocytic leukemia.
  • Conducted a retrospective analysis of patients with relapsed/refractory T-PLL treated with venetoclax-based regimens.
  • Treatment response was assessed using established consensus criteria.
  • Analyzed patient demographics, previous treatments, and response outcomes.
  • Among 35 patients, the overall response rate was 46%, with notable responses in 1st salvage therapy.
  • Survival analysis indicated a median overall survival of 4.3 months for the cohort, with better outcomes in responders.
  • Twelve patients experienced tumor lysis syndrome, and significant rates of neutropenia and thrombocytopenia were reported.

Cite This Study

Vega et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e20ahttps://doi.org/10.1182/blood-2025-3653
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Response to venetoclax-containing regimens in patients with relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL).2026
  2. 2Outcomes of therapy‐related non‐core binding factor acute myeloid leukemia with venetoclax‐based therapies2026
  3. 3Efficacy of venetoclax in the treatment of relapsed/refractory light-chain amyloidosis2025
  4. 4Venetoclax plus inotuzumab ozogamicin for relapsed and refractory ALL: Results of a phase I trial2025 · 2 citations
  5. 5Venetoclax-based treatment in adult relapsed/refractory acute lymphoblastic leukemia and lymphoblastic lymphoma: a single-center real-world experience2026